剑桥的一项研究显示,在患有BRCA突变的激进乳腺癌患者中,一种新的治疗方法实现了100%的存活率。 A Cambridge study shows a new treatment achieving 100% survival in aggressive breast cancer patients with BRCA mutations.

剑桥的一项新研究表明,对患有与BRCA1和BRCA2基因突变有关的具有攻击性、遗传性乳腺癌的病人进行了开创性的治疗。 A new study from Cambridge shows a groundbreaking treatment for patients with aggressive, inherited breast cancers linked to BRCA1 and BRCA2 gene mutations. 经过试验治疗的接受化疗的病人,在手术前先服用药用olaparib,导致手术后3年的存活率达到100%。 The trial treated patients with chemotherapy followed by the drug olaparib before surgery, resulting in a 100% survival rate three years post-surgery. 研究还发现,治疗之间的48小时差距改善了结果。 The study also found that a 48-hour gap between treatments improved outcomes. 研究人员计划进行一次更大的多国试验,以证实这些调查结果,这可能会改变联合王国每年1 200多名病人的临床做法。 Researchers plan a larger multinational trial to confirm these findings, which could change clinical practices for over 1,200 patients annually in the UK.